chr6-56619938-G-A
Variant summary
Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PVS1PM2PP5_Moderate
The NM_001723.7(DST):c.4096C>T(p.Gln1366*) variant causes a stop gained change. The variant allele was found at a frequency of 0.0000041 in 1,461,870 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001723.7 stop_gained
Scores
Clinical Significance
Conservation
Publications
- hereditary sensory and autonomic neuropathy type 6Inheritance: AR Classification: DEFINITIVE, STRONG, MODERATE, SUPPORTIVE, LIMITED Submitted by: Orphanet, Ambry Genetics, G2P, ClinGen, Labcorp Genetics (formerly Invitae)
- epidermolysis bullosa simplex 3, localized or generalized intermediate, with BP230 deficiencyInheritance: AR Classification: STRONG, MODERATE, SUPPORTIVE Submitted by: PanelApp Australia, Ambry Genetics, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 12 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_001723.7. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| DST | NM_001723.7 | MANE Plus Clinical | c.4096C>T | p.Gln1366* | stop_gained | Exon 23 of 24 | NP_001714.1 | ||
| DST | NM_001374736.1 | MANE Select | c.4929+4592C>T | intron | N/A | NP_001361665.1 | |||
| DST | NM_001374734.1 | c.4956+4592C>T | intron | N/A | NP_001361663.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| DST | ENST00000370765.11 | TSL:1 MANE Plus Clinical | c.4096C>T | p.Gln1366* | stop_gained | Exon 23 of 24 | ENSP00000359801.6 | ||
| DST | ENST00000680361.1 | MANE Select | c.4929+4592C>T | intron | N/A | ENSP00000505098.1 | |||
| DST | ENST00000244364.10 | TSL:1 | c.3318+4592C>T | intron | N/A | ENSP00000244364.6 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD2 exomes AF: 0.00000796 AC: 2AN: 251208 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 0.00000410 AC: 6AN: 1461870Hom.: 0 Cov.: 36 AF XY: 0.00000275 AC XY: 2AN XY: 727232 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary sensory and autonomic neuropathy type 6;C3809470:Epidermolysis bullosa simplex 3, localized or generalized intermediate, with BP230 deficiency Pathogenic:1
This variant has not been reported in the literature in individuals with DST-related disease. This sequence change creates a premature translational stop signal (p.Gln1366*) in the DST gene. It is expected to result in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). Loss-of-function variants in DST are known to be pathogenic (PMID: 25059916). For these reasons, this variant has been classified as Pathogenic.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at